U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 31 - 40 of 132,111 results

Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Pacritinib (SB1518), discovered in Singapore at the labs of S*BIO Pte Ltd., is an oral tyrosine kinase inhibitor (TKI) with activity against two important activating mutations: Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). T...
Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Mitapivat, also known as PKM2 activator 1020, is an activator of a pyruvate kinase PKM2, an enzyme involved in glycolysis. It was disclosed in a patent publication WO 2011002817 A1 as compound 78.
Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (MIXED)

Status:
US Approved Rx (2023)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)



Bexagliflozin, also known as EGT1442, is a potent and selective SGLT2 inhibitor. Bexagliflozin is under investigation for the treatment of Type 2 Diabetes Mellitus. Bexagliflozin has been investigated for the treatment of Diabetes Mellitus and Type2 ...